Q3 2018 13F Holders as of 9/30/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
145M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
67M
-
Shares change
-
+4.76M
-
Total reported value, excl. options
-
$1.46B
-
Value change
-
+$109M
-
Number of buys
-
53
-
Number of sells
-
-19
-
Price
-
$21.74
Significant Holders of Denali Therapeutics Inc. - Common Stock (DNLI) as of Q3 2018
85 filings reported holding DNLI - Denali Therapeutics Inc. - Common Stock as of Q3 2018.
Denali Therapeutics Inc. - Common Stock (DNLI) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67M shares
of 145M outstanding shares and own 46.11% of the company stock.
Largest 10 shareholders include Crestline Management, LP (20.6M shares), Flagship Pioneering Inc. (8.92M shares), FMR LLC (7.71M shares), BAILLIE GIFFORD & CO (5.49M shares), Vanguard Group Inc (4.83M shares), Temasek Holdings (Private) Ltd (4.41M shares), BlackRock Inc. (3.31M shares), FIL Ltd (2.79M shares), LORD, ABBETT & CO. LLC (1.13M shares), and BAMCO INC /NY/ (955K shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.